PlexusDx sidesteps this risk entirely by offering transparent upfront pricing with no surprise authorizations or coverage determinations
For them, GLP-1s can be a good option to help maintain their weight loss
Le smaglutide est un agoniste de GLP1
Critical Price Increases (December 2025 - March 2026): Ingredient Price Increase Primary Use Thiocolchicide 106% Muscle relaxant Glycerin 64% Solvent, excipient Nimesulide 53% Pain relief Deflazacort 50% Steroid Clobetasol Propionate 47% Skin treatment Amoxicillin Trihydrate 45% Antibiotic Paracetamol 26% Fever, pain Diclofenac Sodium 25-30% Anti-inflammatory Ciprofloxacin 20-30% Antibiotic Solvents (IPA, Acetone) 20-30% Manufacturing Multiple Factors Driving Crisis: Rupee depreciation against US dollar Petroleum-linked solvent costs (oil at $115/barrel) Container shortages and vessel delays from China Opportunistic pricing by some suppliers Industry Response: The Federation of Pharma Entrepreneurs has formally requested NPPA intervention, seeking permission for price hikes under DPCO 2013 Para 19
Saeed WK, Jun DW, Jang K, Oh JH, Chae YJ, Lee JS, et al
Global Oral Non Peptide GLP 1 Receptor Agonist Market Size is valued at USD 102.77 Bn in 2025 and is predicted to reach USD 243.16 Bn by the year 2035 at a 9.2% CAGR during the forecast period for 2026 to 2035